Hepatitis B immune globulin for life versus limited use: I favor limited duration of therapy

Liver Transplantation

Volumn 8, Issue 10 SUPPL. 1, 2002, Pages s90-s91

  Lake, John R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS DELTA VIRUS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; VIRUS DETECTION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0036794645     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35978     Document Type: Article

References (19)

1. Lake JR, Wright TW. Liver transplantation for patients with hepatitis B: What have we learned from our results? Hepatology 1991;13:796-798.
2. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
3. Benner KG, Lee R, Keeffe E, Lopez R, Sasaki A, Pinson C, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992;103:1307-1315.
4. O'Grady J, Smith H, Davies S, Daniels H, Donaldson P, Tan K, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 1992;14:104-109.
5. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528-1535.
6. Terrault NA, Zhou S, Lake JR, Roberts JP, Ascher NL, Hahn J, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:1327-1333.
7. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: A 17-year single-center experience. Ann Surg 2002;235:611-619.
8. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002. Liver Transpl 2002;8:2-9.
9. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28:555-561.
10. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
11. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:436-440.
12. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-894.
13. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, Pillay D. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir. Gut 2001;49:860-863.
14. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-273.
15. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, et al. Lamivudine Compassionate Use Study Group. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transplant 2001;7:504-510.
16. Marzan A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
17. Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2001;48:581.
18. Samuel D. Liver transplantation and hepatitis B virus infection: The situation seems to be under control, but the virus is still there. J Hepatol 2001;34:943-945.
19. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-1674.